Van Ginderdeuren Eva, Allegaert Karel, Decaluwe Herbert, Deprest Jan, Debeer Anne, Proesmans Marijke
Paediatrics (Paediatric Pulmonology),, University Hospitals Leuven, Leuven, Belgium.
Neonatology. 2017;112(4):365-371. doi: 10.1159/000479145. Epub 2017 Sep 2.
Congenital diaphragmatic hernia (CDH) is an abnormal development of the diaphragm leading to high neonatal mortality and morbidity. Beyond the neonatal period, prospective data on overall long-term outcome in CDH survivors is scarce. In particular, for those treated with fetoscopic endoluminal tracheal occlusion (FETO), a promising new technique to increase survival chances for severe cases, the outcomes are even less documented.
To prospectively document the clinical outcome of CDH at 1 year including FETO-treated infants in relation to ante- and postnatal variables.
A single-centre prospective clinical follow-up at 1 year of age included a standardised respiratory questionnaire.
Thirty-four CDH survivors were included, 10 of which were FETO-treated infants. At 1 year, the median weight z score was -1.50 (interquartile range [IQR]: -2.45 to -0.88) and 10/34 were "failure to thrive" (FTT) cases. Gastro-intestinal (GI) problems at 1 year were mainly related to gastro-oesophageal reflux (16/34) with a high need for tube feeding in the first year (9/34). Tachypnoea was present in 10/29 (34%) and 8/34 (24%) were on chronic inhaled medication. The median total respiratory symptom score was 20 (IQR: 13-32) and correlated with the number of neonatal ventilation days (p = 0.048). Hospital re-admission occurred in 19/34 infants (56%), and was for respiratory problems in almost half of them (8/19).
In this CDH cohort, morbidity at 1 year was determined more by GI problems and FTT than respiratory morbidity. The respiratory questionnaire may, however, have underestimated the respiratory morbidity since respondents had a 1-in-4 chance to have persistent tachypnoea and be on chronic inhalation therapy.
先天性膈疝(CDH)是膈肌的一种异常发育,导致新生儿高死亡率和高发病率。在新生儿期之后,关于CDH幸存者总体长期预后的前瞻性数据很少。特别是对于那些接受胎儿镜下腔内气管阻塞术(FETO)治疗的患者,这是一种有望提高重症病例存活几率的新技术,其预后记录更少。
前瞻性记录CDH患儿1岁时的临床结局,包括接受FETO治疗的婴儿,并分析其与产前和产后变量的关系。
在单中心对1岁患儿进行前瞻性临床随访,包括一份标准化的呼吸问卷。
纳入了34名CDH幸存者,其中10名是接受FETO治疗的婴儿。1岁时,体重Z评分中位数为-1.50(四分位间距[IQR]:-2.45至-0.88),10/34为“生长发育迟缓”(FTT)病例。1岁时的胃肠道(GI)问题主要与胃食管反流有关(16/34),第一年对管饲的需求很高(9/34)。29名中有10名(34%)存在呼吸急促,34名中有8名(24%)接受慢性吸入药物治疗。呼吸症状总评分中位数为20(IQR:13 - 32),与新生儿通气天数相关(p = 0.048)。19/34名婴儿(56%)再次入院,其中近一半(8/19)是因为呼吸问题。
在这个CDH队列中,1岁时的发病率更多地由GI问题和FTT决定,而非呼吸疾病。然而,呼吸问卷可能低估了呼吸疾病的发病率,因为受访者有四分之一的几率持续呼吸急促并接受慢性吸入治疗。